We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
After another slow year for IPOs in 2023 – following an equally dismal 2022 – the ASX is set to see...
Read ArticleThe Anteris Technologies Ltd (ASX: AVR) share price is shooting for the stars in early afternoon tr...
Read ArticleShareCafeHeart Innovator Anteris Takes on Medical Device Giants It’s been a rocky corporate journey...
Read ArticleThe Anteris Technologies Ltd (ASX: AVR) share price is plunging today despite the company declaring...
Read ArticleThe Anteris Technologies Ltd (ASX: AVR) share price rose a jaw-dropping 23% today after an online i...
Read ArticleAnteris Technologies Ltd (ASX: AVR) shares will be on watch this morning following the release of t...
Read ArticleThe Anteris Technologies Ltd (ASX: AVR) share price is edging higher today after releasing the resu...
Read ArticleAnteris is a structural heart company with technology, ADAPT® and DurAVR™, that solves critical issu...
Read ArticleThe aim of this study is to evaluate anti-calcification properties in the established subcutaneous r...
Read ArticleThe aim of this study is to evaluate anti-calcification properties in the established subcutaneous r...
Read ArticleThe company is focused on bringing DurAVR™ to market, building on the company’s cardiovascular patch...
Read ArticleThe company’s aortic valve, DurAVR™ was successfully implanted into the first patient at the Univers...
Read ArticleThe first-in-human surgical aortic valve replacement (SAVR) trial is underway, with the first patien...
Read ArticleFifteen patients have been enrolled in the study and will be followed up for 6 months after receivin...
Read ArticleThe company is conducting the first-in-hiuman surgical aortic valve study.
Read ArticleThe company is focused on continuing to manufacture clinical solutions for healthcare professionals.
Read ArticleThe first-in-human surgical aortic valve replacement study can now go ahead as planned starting this...
Read ArticleTotal revenue for the company was $17.1 million, which includes $10.2 million from sales of ADAPT® p...
Read Article4C Medical’s implant utilises tissue processed by Admedus’ ADAPT Tissue Engineering Process for the...
Read ArticleThe debut of Admedus' innovation suite at the world’s largest structural heart valve congress, PCR L...
Read ArticleAdmedus (ASX:AHZ) has announced the approval for first-in-human surgical aortic valve replac...
Read ArticleAdmedus (AHZ) has received approval for the first in-human surgical aortic valve replacement trial...
Read ArticleThe proposal follows Professor Meuris’ confidence in the prototype aortic valve after his recent inv...
Read ArticleAsia is rising as a healthcare spender, matching incomes and the long-feared elderly population boom...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleLeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral va...
Read ArticleShares have increased by around 50% this week after hitting 10.5 cents yesterday.
Read ArticleOn this day in 1923, the Walt Disney Company was founded. A leader in the international entertainmen...
Read ArticleInvestors responded after Admedus was reinstated to official quotation, with shares surging 40% to a...
Read ArticleAdmedus (ASX: AHZ) shares have returned to trading after the structural heart company confirmed it w...
Read ArticleCardioCel 3D® is used by surgeons to repair heart valves.
Read ArticleCardioCel 3D® is used by surgeons to repair heart valves.
Read ArticleIn this week’s recap of substantial holders, James Baillieu has bought into Candy Club (ASX: CLB), W...
Read ArticleInvex Therapeutics Ltd (ASX: IXC) shares have now doubled from their July 3 initial public offer pr...
Read ArticleIn this week’s recap of substantial holder movements four substantial holders bought shares in Zenit...
Read ArticleAdmedus (ASX:AHZ) has announced the publication of an independent study assessing the perfor...
Read ArticleEarbuds maker Nuheara (ASX:NUH) surprised and dismayed the market this morning telling investors it...
Read ArticleThe study had positive outcomes, showing that the valve replacement devices had good durability.
Read ArticleUp until about four years ago obesity was an ‘it’ investment trend, as global funds spruiked the ‘su...
Read ArticleUp until about four years ago obesity was an ‘it’ investment trend, as global funds spruiked the ‘su...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
